Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

MLA

Eyre, Toby A., et al. “Efficacy of Venetoclax Monotherapy in Patients with Relapsed Chronic Lymphocytic Leukaemia in the Post-BCR Inhibitor Setting: A UK Wide Analysis.” British Journal of Haematology, vol. 185, no. 4, May 2019, pp. 656–69. EBSCOhost, https://doi.org/10.1111/bjh.15802.

APA

Eyre, T. A., Kirkwood, A. A., Gohill, S., Follows, G., Walewska, R., Walter, H., Cross, M., Forconi, F., Shah, N., Chasty, R., Hart, A., Broom, A., Marr, H., Patten, P. E. M., Dann, A., Arumainathan, A., Munir, T., Shankara, P., Bloor, A., … Fox, C. P. (2019). Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. British Journal of Haematology, 185(4), 656–669. https://doi.org/10.1111/bjh.15802

Chicago

Eyre, Toby A, Amy A Kirkwood, Sat Gohill, George Follows, Renata Walewska, Harriet Walter, Matthew Cross, et al. 2019. “Efficacy of Venetoclax Monotherapy in Patients with Relapsed Chronic Lymphocytic Leukaemia in the Post-BCR Inhibitor Setting: A UK Wide Analysis.” British Journal of Haematology 185 (4): 656–69. doi:10.1111/bjh.15802.